TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30503844

Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP)
Number of subjects: 7787

Group type: EXPERIMENTAL
Intervention: Cholecystectomy
Number of subjects: 7787

Group type: EXPERIMENTAL
Intervention: 30-day readmission
Number of subjects: 7787

Group type: EXPERIMENTAL
Intervention: Severe acute pancreatitis (SAP)
Number of subjects: 7787

Group type: EXPERIMENTAL
Intervention: Weekend admission
Number of subjects: 7787

Group type: EXPERIMENTAL
Intervention: >1 week of hospitalization
Number of subjects: 7787

Group type: EXPERIMENTAL
Intervention: ERCP
Number of subjects: 7787
Study: 28632204

Group type: EXPERIMENTAL
Intervention: Behavioral Intervention (BI)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Behavioral Intervention plus d‐cycloserine (BI+DCS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 15
Study: 25713096

Group type: EXPERIMENTAL
Intervention: Hybrid format (online delivery)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional format (in-person delivery)
Number of subjects: 0
Study: 23391728

Group type: EXPERIMENTAL
Intervention: Personalised intervention for depression and COPD (PID‐C)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 138
Study: 21054800

Group type: EXPERIMENTAL
Intervention: Topical misoprostol (100 µg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 17853018

Group type: EXPERIMENTAL
Intervention: Bilateral periprostatic infiltration of 5 cm(3) of 2% lidocaine
Number of subjects: 160

Group type: COMPARATOR
Intervention: Bilateral periprostatic infiltration of 5 cm(3) of 0.9% saline solution
Number of subjects: 160
Study: 15913843

Group type: EXPERIMENTAL
Intervention: Choline acetyltransferase (ChAT) activity in PDD cases
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Choline acetyltransferase (ChAT) activity in DLB + P cases
Number of subjects: 39

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 39

Group type: COMPARATOR
Intervention: DLB - P
Number of subjects: 39

Group type: COMPARATOR
Intervention: PD
Number of subjects: 39
Study: 15493518

Group type: EXPERIMENTAL
Intervention: Patella taping combined with a standardized exercise program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo patella taping and exercise program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Exercise program alone
Number of subjects: 30
Study: 11309457

Group type: EXPERIMENTAL
Intervention: Acute stroke unit
Number of subjects: 121

Group type: COMPARATOR
Intervention: General medical wards
Number of subjects: 121
Study: 9116938

Group type: EXPERIMENTAL
Intervention: Laparoscopic
Number of subjects: 38

Group type: COMPARATOR
Intervention: Lichtenstein
Number of subjects: 38
Study: 7840587

Group type: EXPERIMENTAL
Intervention: Famciclovir
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3000
Study: 2896828

Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb (E-Z) measles vaccine, 40,000 plaque forming units
Number of subjects: 74

Group type: COMPARATOR
Intervention: Schwarz vaccine, 40,000 plaque forming units
Number of subjects: 74
Study: 30431581

Group type: EXPERIMENTAL
Intervention: Kaolin-filled pad (QuikClot)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Conventional hemostasis
Number of subjects: 260
Study: 28402415

Group type: EXPERIMENTAL
Intervention: Single-dose misoprostol (800 μg vaginally on Day 1)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Repeat-dose misoprostol (800 μg vaginally on Day 1, with a second dose if required on Day 4)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Repeat-dose misoprostol
Number of subjects: 160

Group type: COMPARATOR
Intervention: Single-dose misoprostol
Number of subjects: 160
Study: 26185033

Group type: EXPERIMENTAL
Intervention: BMP-2/H (1 mg/mL of rhBMP-2 soaked with hydroxyapatite granules, 0.5 to 2.0 g; n = 65)
Number of subjects: 127

Group type: COMPARATOR
Intervention: ABX (inorganic bovine bone xenograft, 0.5 to 2.0 g; n = 62)
Number of subjects: 127
Study: 23295964

Group type: EXPERIMENTAL
Intervention: Combined hepatitis A and hepatitis B vaccine (first dose)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Combined hepatitis A and hepatitis B vaccine (third dose)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Combined hepatitis A and hepatitis B vaccine (first booster dose)
Number of subjects: 283
Study: 21365662

Group type: EXPERIMENTAL
Intervention: GSM 900
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: WCDMA
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Time-of-day effects
Number of subjects: 30
Study: 18480196

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 2331

Group type: COMPARATOR
Intervention: Tranexamic acid
Number of subjects: 2331

Group type: COMPARATOR
Intervention: Aminocaproic acid
Number of subjects: 2331
Study: 16568143

Group type: EXPERIMENTAL
Intervention: 3 Hz cutaneous electrical stimulation in patients with SCI
Number of subjects: 75

Group type: COMPARATOR
Intervention: 3 Hz cutaneous electrical stimulation in control subjects
Number of subjects: 75
Study: 14658976

Group type: EXPERIMENTAL
Intervention: Long-acting injectable risperidone (25 mg, 50 mg, or 75 mg every 2 weeks for 12 months)
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Long-acting injectable risperidone
Number of subjects: 615
Study: 10623910

Group type: EXPERIMENTAL
Intervention: PWP-GT model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TT-R model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WLW model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LWA model
Number of subjects: 0
Study: 9179067

Group type: EXPERIMENTAL
Intervention: Nonabsorbable antibiotic lozenge
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 8482427

Group type: EXPERIMENTAL
Intervention: Multiple logistic regression models
Number of subjects: 1485

Group type: COMPARATOR
Intervention: Impaired glucose tolerance
Number of subjects: 1485
Study: 2869679

Group type: EXPERIMENTAL
Intervention: Bucindolol 50 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Bucindolol 200 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 29469926

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation throughout pregnancy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Folic acid supplementation during the first trimester
Number of subjects: 39
Study: 27612561

Group type: EXPERIMENTAL
Intervention: High Intensity (HI) exercise program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-to-Moderate Intensity (LMI) exercise program
Number of subjects: 0
Study: 26509172

Group type: EXPERIMENTAL
Intervention: Media campaign and clinic intervention focused on CRC screening
Number of subjects: 1123

Group type: COMPARATOR
Intervention: Comparison group (no specific intervention mentioned)
Number of subjects: 1123
Study: 24307876

Group type: EXPERIMENTAL
Intervention: Aerobic exercise during hemodialysis for 16 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no aerobic exercise)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 26
Study: 19557424

Group type: EXPERIMENTAL
Intervention: Cocktail therapy (ESWT, HBO, alendronate)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Extracorporeal shock wave treatment (ESWT) alone
Number of subjects: 63
Study: 17974698

Group type: EXPERIMENTAL
Intervention: Cell infusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 16042638

Group type: EXPERIMENTAL
Intervention: Nicotine replacement and behavioral therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Compensatory smoking
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spontaneous reduction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relapse after trying to quit
Number of subjects: 0
Study: 12192254

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10518846

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 0.25 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 0.5 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 1.0 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 0.25 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 0.5 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 1.0 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 0.25 mg once daily (study C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 0.5 mg twice daily (study C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 1.0 mg once daily (study C)
Number of subjects: 0
Study: 8748720

Group type: EXPERIMENTAL
Intervention: Topical terbutaline sulfate (1.0 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diluent (placebo)
Number of subjects: 12
Study: 1976563

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 7004292

Group type: EXPERIMENTAL
Intervention: Bethanechol (25 mg tablets, four times daily for 4 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (four times daily for 4 weeks)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Bethanechol
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 31514744

Group type: EXPERIMENTAL
Intervention: Operative treatment (fixation) of medial malleolus fractures
Number of subjects: 154

Group type: COMPARATOR
Intervention: Non-operative treatment (non-fixation) of medial malleolus fractures
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Operative treatment (fixation)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Non-operative treatment (non-fixation)
Number of subjects: 154
Study: 28990241

Group type: EXPERIMENTAL
Intervention: Clinically indicated replacement of peripheral intravenous catheters (PIVC)
Number of subjects: 1198

Group type: COMPARATOR
Intervention: Routine replacement of peripheral intravenous catheters (PIVC) every 72-96 hours
Number of subjects: 1198
Study: 25381876

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 274

Group type: COMPARATOR
Intervention: Placebo + low-dose metformin
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Dapagliflozin groups
Number of subjects: 274
Study: 24289915

Group type: EXPERIMENTAL
Intervention: Lifitegrast ophthalmic solution 5.0%
Number of subjects: 588

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 588
Study: 23781653

Group type: EXPERIMENTAL
Intervention: Brahma‐muhurtha group (rising before 4:30 am)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (waking just before 7 am)
Number of subjects: 54
Study: 19741313

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (25 g/day for 7 days, then 5 g/day for 14 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (50 g/day glucose for 7 days, then 30 g/day glucose for 14 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 20
Study: 17559754

Group type: EXPERIMENTAL
Intervention: Tramadol ER (100 mg, 200 mg, 300 mg, or 400 mg once daily)
Number of subjects: 1020

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Tramadol ER
Number of subjects: 1020
Study: 11103755

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8726237

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin, s.c. 200 U/kg of body weight three times a week for 6 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1416575

Group type: EXPERIMENTAL
Intervention: Color Doppler ultrasound
Number of subjects: 385

Group type: COMPARATOR
Intervention: Contrast venography
Number of subjects: 385
Study: 2933205

Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31221619

Group type: EXPERIMENTAL
Intervention: Epacadostat 100 mg orally twice daily plus pembrolizumab 200 mg intravenously every 3 weeks
Number of subjects: 706

Group type: COMPARATOR
Intervention: Placebo plus pembrolizumab
Number of subjects: 706

Group type: EXPERIMENTAL
Intervention: Epacadostat plus pembrolizumab
Number of subjects: 706
Study: 30536984

Group type: EXPERIMENTAL
Intervention: Advocacy program for girls
Number of subjects: 0
Study: 28459508

Group type: EXPERIMENTAL
Intervention: Acupoint electric stimulation (AES)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Regular nursing care (RNC)
Number of subjects: 40
Study: 24130088

Group type: EXPERIMENTAL
Intervention: Autologous skeletal myoblast transplantation (ASM-Tx) - low dosage (400 million cells)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Autologous skeletal myoblast transplantation (ASM-Tx) - high dosage (800 million cells)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG) with ASM-Tx
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: All groups (including placebo)
Number of subjects: 7
Study: 22241513

Group type: EXPERIMENTAL
Intervention: Esomeprazole (2.5-10 mg) once daily for 2 weeks, followed by weight-adjusted doses for 4 weeks.
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo for 4 weeks after initial treatment.
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Esomeprazole (2.5-10 mg) for infants with symptomatic GERD.
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo for infants with symptomatic GERD.
Number of subjects: 98
Study: 20090377

Group type: COMPARATOR
Intervention: Individualized parenteral nutrition (IPN)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Standardized parenteral nutrition (SPN)
Number of subjects: 107
Study: 19045968

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group exposure plus response prevention (ERP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group cognitive therapy (CT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exposure plus response prevention (ERP)
Number of subjects: 0
Study: 15911666

Group type: EXPERIMENTAL
Intervention: Transosseous repair with No. 3 Ethibond using modified Mason‐Allen sutures
Number of subjects: 100

Group type: COMPARATOR
Intervention: Transosseous repair with 1.0 mm polydioxanone cord using modified Kessler sutures
Number of subjects: 100
Study: 12771265

Group type: EXPERIMENTAL
Intervention: Idebenone
Number of subjects: 8
Study: 12731753

Group type: EXPERIMENTAL
Intervention: Zanamivir intranasal spray (6.4 mg)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 8730002

Group type: EXPERIMENTAL
Intervention: Integrated care
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: Clinic care
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: Discharged to GP care
Number of subjects: 764
Study: 1656040

Group type: EXPERIMENTAL
Intervention: Lisinopril (10-20 mg once daily)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Metoprolol (100-200 mg once daily)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 360

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 360
Study: 31577749

Group type: EXPERIMENTAL
Intervention: Low-dose misoprostol combined with mifepristone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rivanol combined with mifepristone
Number of subjects: 0
Study: 30172036

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention (8–12 behavioral-education sessions over 12 weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (dialysis education without incorporated CB techniques)
Number of subjects: 48
Study: 27411564

Group type: COMPARATOR
Intervention: UNIMMAP containing 60 mg/d iron (reference arm)
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: UNIMMAP containing 60 mg/d iron based on weekly hepcidin screening
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: UNIMMAP containing 30 mg/d iron for 12 weeks
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 462
Study: 24695898

Group type: EXPERIMENTAL
Intervention: Balanced protein-calorie supplementation during pregnancy and early childhood (1987-1990)
Number of subjects: 1446

Group type: EXPERIMENTAL
Intervention: Current lean mass and weight-bearing physical activity
Number of subjects: 1446

Group type: EXPERIMENTAL
Intervention: Current serum 25-hydroxyvitamin D and dietary intake of calcium, protein, or calories
Number of subjects: 1446
Study: 22283356

Group type: EXPERIMENTAL
Intervention: Mobile phone application for recording symptoms and physical activity exertion, evaluated with the System Usability Scale (SUS) questionnaire 2 months after the intervention.
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Mobile phone diaries for daily symptom reporting via morning and evening questionnaires.
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control group (not specified intervention).
Number of subjects: 158
Study: 20367330

Group type: EXPERIMENTAL
Intervention: Raw fish-free diet for 6 months
Number of subjects: 87

Group type: COMPARATOR
Intervention: Skin prick test for food allergens including Ani s1
Number of subjects: 87
Study: 19186858

Group type: EXPERIMENTAL
Intervention: Self-etching adhesive
Number of subjects: 43

Group type: COMPARATOR
Intervention: Phosphoric acid
Number of subjects: 43
Study: 15946614

Group type: EXPERIMENTAL
Intervention: Respiratory rehabilitation programme
Number of subjects: 476

Group type: COMPARATOR
Intervention: Habitual monitoring
Number of subjects: 476
Study: 12885800

Group type: EXPERIMENTAL
Intervention: Intraperitoneal chromic phosphate suspension (32P) therapy (15 mCi)
Number of subjects: 202

Group type: COMPARATOR
Intervention: No further therapy (NFT)
Number of subjects: 202
Study: 10776506

Group type: EXPERIMENTAL
Intervention: Detection of antiovarian antibody in POF patients
Number of subjects: 18
Study: 8933855

Group type: EXPERIMENTAL
Intervention: Atropine premedication (0.01 mg/kg intramuscularly 30 min before procedure)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No atropine premedication (control group)
Number of subjects: 28
Study: 1896817

Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole (140 mg/day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole (200 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole (both doses)
Number of subjects: 10
Study: 7160549

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Acarbose without Metronidazole)
Number of subjects: 0
Study: 30897454

Group type: EXPERIMENTAL
Intervention: Active calf muscle electrical stimulation (ES)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham electrical stimulation
Number of subjects: 16
Study: 26817648

Group type: EXPERIMENTAL
Intervention: 12-week exercise intervention with telephone coaching
Number of subjects: 63

Group type: COMPARATOR
Intervention: Usual care plus telephone calls
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Self-management exercise programme (adherence > 75%)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Physical activity, functional ability and health-related quality of life measures
Number of subjects: 63
Study: 26104223

Group type: EXPERIMENTAL
Intervention: Cervical infiltration with botulinum toxin
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Group problem-solving therapy
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 66
Study: 24676798

Group type: EXPERIMENTAL
Intervention: Disordered eating attitudes
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Unhealthy weight control behaviors (UWCBs)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Disordered eating attitudes and weight status
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Disordered eating attitudes and UWCBs
Number of subjects: 272
Study: 21846056

Group type: EXPERIMENTAL
Intervention: Hydazepam and succinic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: No pharmacological correction
Number of subjects: 0
Study: 19398471

Group type: EXPERIMENTAL
Intervention: Computerised decision support
Number of subjects: 2787
Study: 17078084

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CyA)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate sodium (PPS)
Number of subjects: 64
Study: 16375656

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63

Group type: COMPARATOR
Intervention: Low-function controls
Number of subjects: 63

Group type: COMPARATOR
Intervention: MCI
Number of subjects: 63

Group type: COMPARATOR
Intervention: AD
Number of subjects: 63
Study: 11927789

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study: 9616446

Group type: EXPERIMENTAL
Intervention: Pilocarpine hydrochloride (Salagen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Artificial saliva (Saliva Orthana)
Number of subjects: 0
Study: 7649340

Group type: EXPERIMENTAL
Intervention: Astemizole-D (10 mg astemizole/240 mg pseudoephedrine)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Loratadine-D (5 mg loratadine/120 mg pseudoephedrine)
Number of subjects: 240
Study: 2668051

Group type: EXPERIMENTAL
Intervention: Fructose (50 g)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Glucose (50 g)
Number of subjects: 6
Study: 1067352

Group type: EXPERIMENTAL
Intervention: Combined preventive measures including ingestion of fluoridated water (1.0 ppm), topical application of acidulated phosphate fluoride, application of a pit and fissure sealant, early detection of caries, restoration of affected teeth, and dental health education.
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Dental health education program and consumption of fluoridated water (1.0 ppm).
Number of subjects: 1200